A Phase 1 Study of Fosbretabulin in Combination With Everolimus in Neuroendocrine Tumors (Grades 1-3) That Have Progressed After at Least One Prior Regimen for Metastatic Disease

This is a single center, open label, phase I study involving grade I-III gastroenteropancreatic neuroendocrine tumors, consisting of a dose escalation Part A followed by an expansion cohort Part B. On Part A Patients will be treated with daily oral everolimus. Fosbretabulin will be administered IV either q3 weekly or q weekly based on PO CRM cohort. Part B: Once the investigators have established an MTD in Part A, the investigators will be treating 15 more patients at that dose combination. The primary and secondary objectives of the expansion cohort will be similar to Part A of the study, i.e., to establish a safety profile of the experimental drug combination and to collect and assess efficacy data. Patients will be treated with concurrent everolimus and fosbretabulin for 12 weeks.

Start Date06 Mar 2017

Sponsor / Collaborator

University of Kentucky

NCT01701349 / WithdrawnPhase 3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Fosbretabulin Tromethamine (CA4P) in Combination With Paclitaxel and Carboplatin in Anaplastic Thyroid Carcinoma (FACT2)

This is a multicenter, double-blind, placebo-controlled, randomized study of fosbretabulin given with chemotherapy (paclitaxel and carboplatin) compared to placebo given with chemotherapy (paclitaxel and carboplatin) in subjects with anaplastic thyroid cancer (ATC). The primary objective of the study is to determine overall survival. A maximum of 300 subjects will be recruited from approximately 75 multinational sites of which approximately 35 will be located in the United States.

Start Date01 Mar 2015

Sponsor / Collaborator

Oncotelic Therapeutics, Inc.

NCT02279602 / CompletedPhase 2

Rollover for Study OX4218s, A P2 Study to Investigate Safety and Activity of Fosbretabulin Tromethamine in the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic PNET or GI-NET With Elevated Biomarkers

Subjects achieving a clinical response in study OX4218s with a biomarker reduction or symptom response are eligible to enroll in this rollover study to continue once every three weeks fosbretabulin infusions for up to one year.

Start Date01 Dec 2014

Sponsor / Collaborator

Oncotelic Therapeutics, Inc.

100 Clinical Results associated with Disodium combretastatin A-4 3-O-Phosphate

100 Translational Medicine associated with Disodium combretastatin A-4 3-O-Phosphate

100 Patents (Medical) associated with Disodium combretastatin A-4 3-O-Phosphate

745

Literatures (Medical) associated with Disodium combretastatin A-4 3-O-Phosphate

01 Jan 2025·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

A novel life for antitumor combretastatins: Recent developments of hybrids, prodrugs, combination therapies, and antibody-drug conjugates

Review

Author: Carradori, Simone ; Fantacuzzi, Marialuigia ; De Filippis, Barbara ; Ammazzalorso, Alessandra ; Giampietro, Letizia ; Maccallini, Cristina ; Amoroso, Rosa

Since their discovery from natural sources, the potent cytotoxic effects of combretastatins were widely studied for the application in antitumor therapy. However, major pharmacokinetic issues as low water solubility and chemical instability of the double bond configuration prevented their use in therapy. A lot of efforts have been directed towards the search of novel strategies, allowing a safer use of combretastatins as anticancer agents. This review analyses the recent landscape in combretastatin research, characterized by the identification of hybrids, prodrugs, and novel combination treatments. Interestingly, the potent cytotoxic agent combretastatin A4 (CA4) was recently proposed as payload in the construction of novel antibody-drug conjugates (ADCs), allowing an efficient targeting of the cytotoxic agent to specific tumors.

07 Aug 2024·ACS Applied Materials & Interfaces

Peptide-IR820 Conjugate: A Promising Strategy for Efficient Vascular Disruption and Hypoxia Induction in Melanoma

Article

Author: Jiang, Mengmeng ; Zheng, Zhen ; Li, Gongyu ; Zhang, Hongxia ; Xing, Weiyu ; Zhao, Rui

Photothermal therapy (PTT) has emerged as a noninvasive and precise cancer treatment modality known for its high selectivity and lack of drug resistance. However, the clinical translation of many PTT agents is hindered by the limited biodegradability of inorganic nanoparticles and the instability of organic dyes. In this study, a peptide conjugate, IR820-Cys-Trp-Glu-Trp-Thr-Trp-Tyr (IR820-C), was designed to self-assemble into nanoparticles for both potent PTT and vascular disruption in melanoma treatment. When co-assembled with the poorly soluble vascular disrupting agent (VDA) combretastatin A4 (CA4), the resulting nanoparticles (IR820-C@CA4 NPs) accumulate efficiently in tumors, activate systemic antitumor immune responses, and effectively ablate melanoma with a single treatment and near-infrared irradiation, as confirmed by our in vivo experiments. Furthermore, by exploiting the resulting tumor hypoxia, we subsequently administered the hypoxia-activated prodrug tirapazamine (TPZ) to capitalize on the created microenvironment, thereby boosting therapeutic efficacy and antimetastatic potential. This study showcases the potential of short-peptide-based nanocarriers for the design and development of stable and efficient photothermal platforms. The multifaceted therapeutic strategy, which merges photothermal ablation with vascular disruption and hypoxia-activated chemotherapy, holds great promise for advancing the efficacy and scope of cancer treatment modalities.

01 Jun 2024·INVESTIGATIONAL NEW DRUGS

In vitro results with minimal blood toxicity of a combretastatin A4 analogue

Article

Author: Barreiro, Eliezer J ; Schumacher, Maria Lúcia ; Britos, Tatiane Nassar ; Lima, Lídia Moreira ; Petri, Giuliana ; da Costa Aguiar Alves Reis, Beatriz ; Haddad, Paula Silvia ; Ferreira, Fabio Furlan ; Mansano, Jaqueline Vital ; Chagas, Camila ; Fonseca, Fernando Luiz Affonso ; da Silva, Emerson Barbosa ; Pereira, Edimar Cristiano

Cancer is a disease caused by uncontrolled cell growth that is responsible for several deaths worldwide. Breast cancer is the most common type of cancer among women and is the leading cause of death. Chemotherapy is the most commonly used treatment for cancer; however, it often causes various side effects in patients. In this study, we evaluate the antineoplastic activity of a parent compound based on a combretastatin A4 analogue. We test the compound at 0.01 mg mL^- 1, 0.1 mg mL^- 1, 1.0 mg mL^- 1, 10.0 mg mL^- 1, 100.0 mg mL^- 1, and 1,000.0 mg mL^- 1. To assess molecular antineoplastic activity, we conduct in vitro tests to determine the viability of Ehrlich cells and the blood mononuclear fraction. We also analyze the cytotoxic behavior of the compound in the blood and blood smear. The results show that the molecule has a promising antineoplastic effect and crucial anticarcinogenic action. The toxicity of blood cells does not show statistically significant changes.

News (Medical) associated with Disodium combretastatin A-4 3-O-Phosphate

06 Nov 2024

·www.globenewswire.com

ONCOTELIC CLINICAL PRESENTATIONS AT SITC 2024

AGOURA HILLS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at SITC 2024. Dr. Cynthia Lee, VP of R&D will be presenting Sapu Bio pipeline of TGFB2 therapeutics. For additional information please go to: https://www.sitcancer.org/home. Dr. Lee has been leading our R&D programs for the past several years including the buildout of our GMP facility in San Diego. The presentations are: Abstract Number 198: TGFB2 mRNA levels prognostically interact with Interferon-alpha receptor activation of IRF9 and IFI27, and makers for tumor-associated macrophages impacting overall survival in PDAC. Authors Sanjive Qazi, Cynthia Lee, Vuong Trieu Abstract Number 218: Evaluating the prognostic impact of Transforming growth factor beta 2 mRNA levels, in conjunction with Interferon-gamma receptor activation of IRF5 and expression of CD276/B7-H3 in low-grade gliomas. Authors Sanjive Qazi, Anthony Maida, Vuong Trieu Abstract Number 1444: Meta-analysis comparing the incidence of serious adverse events, overall survival, and progression-free survival in PDAC patients harboring unresectable tumors treated with mFOLFIRINOX or FOLFIRINOX. Authors Vuong Trieu, Sanjive Qazi, Seymour Fein, Anthony Maida, Tenshang Joh About Oncotelic Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG” through OT-101) through its 45% joint venture, GMP Biotechnology Limited, melanoma (through CA4P), and Acute Myeloid Leukemia (through OXi 4503). Oncotelic acquired PointR Data Inc. in November 2019 to build an AI driven biotechnology company. Further, Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease, erectile dysfunction, female sexual disorder and hypoactive sexual desire disorder. All these ailments have a very large population suffering from them and there is a need for treatments for each. Oncotelic’s first in class TGFB2 therapeutic to treat pancreatic cancer and glioblastoma is being developed through its JV – Sapu Bio. Oncotelic's Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the Company’s product candidates and the potential use of the Company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the development of the Company’s AI suite including but not limited to AI Chatbots, the public access to the Company’s AI suite, the success of the development of the AI suite or any other AI technologies and whether if any or portion thereof the Company’s AI suite or technologies will be commercialized and launched for sale. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's Annual Report on Form 10-K/A filed with the SEC on April 19, 2023 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise. Contact Information: For Oncotelic Therapeutics, Inc.:Investor Relationsir@oncotelic.com

AcquisitionmRNA

28 Oct 2024

·www.globenewswire.com

ONCOTELIC PUBLISHED ITS FOURTH PUBLICATION ON TGFB2 THERAPEUTICS

AGOURA HILLS, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its fourth publication of its TGFB2 series. Clinical data demonstrated that pancreatic cancer patients with high expression levels of either TGFB2, IRF9, or IFI27 showed improvement of median overall survival from 16-20 months to 72 months for patients with low levels of expression for both TGFB2 and either IRF9 or IFI27 validating that knockdown of IRF9 and IFI27 as therapeutic targets for TGFB2 therapeutics. https://www.mdpi.com/3003472 The publications of this series are available at Pubmed as follow: 1) TGFB2 mRNA Levels Prognostically Interact with Interferon-Alpha Receptor Activation of IRF9 and IFI27, and an Immune Checkpoint LGALS9 to Impact Overall Survival in Pancreatic Ductal Adenocarcinoma. Qazi S, Trieu V. Int J Mol Sci. 2024 Oct 18;25(20):11221. doi: 10.3390/ijms252011221. PMID: 39457004 2) Transforming Growth Factor Beta 2 (TGFB2) mRNA Levels, in Conjunction with Interferon-Gamma Receptor Activation of Interferon Regulatory Factor 5 (IRF5) and Expression of CD276/B7-H3, Are Therapeutically Targetable Negative Prognostic Markers in Low-Grade Gliomas. Trieu V, Maida AE, Qazi S. Cancers (Basel). 2024 Mar 19;16(6):1202. doi: 10.3390/cancers16061202. PMID: 38539537 Free PMC article. 3) Transforming Growth Factor Beta 2 (TGFB2) and Interferon Gamma Receptor 2 (IFNGR2) mRNA Levels in the Brainstem Tumor Microenvironment (TME) Significantly Impact Overall Survival in Pediatric DMG Patients. Qazi S, Talebi Z, Trieu V. Biomedicines. 2024 Jan 15;12(1):191. doi: 10.3390/biomedicines12010191. PMID: 38255296 Free PMC article. 4) High Intra-Tumor Transforming Growth Factor Beta 2 Level as a Predictor of Poor Treatment Outcomes in Pediatric Diffuse Intrinsic Pontine Glioma. Uckun FM, Qazi S, Trieu V. Cancers (Basel). 2023 Mar 9;15(6):1676. doi: 10.3390/cancers15061676. PMID: 36980562 Free PMC article. Additional information on our current phase 3 can be found at: https://www.youtube.com/watch?v=5KqdbySDRKE About Oncotelic Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG” through OT-101) through its 45% joint venture, GMP Biotechnology Limited, melanoma (through CA4P), and Acute Myeloid Leukemia (through OXi 4503). Oncotelic acquired PointR Data Inc. in November 2019 to build an AI driven biotechnology company. Further, Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease, erectile dysfunction, female sexual disorder and hypoactive sexual desire disorder. All these ailments have a very large population suffering from them and there is a need for treatments for each. For more information on AL-101, refer to our Annual Report on Form 10-K/A filed with the SEC on April 19, 2023. Oncotelic's Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the Company’s product candidates and the potential use of the Company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the development of the Company’s AI suite including but not limited to AI Chatbots, the public access to the Company’s AI suite, the success of the development of the AI suite or any other AI technologies and whether if any or portion thereof the Company’s AI suite or technologies will be commercialized and launched for sale. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's Annual Report on Form 10-K/A filed with the SEC on April 19, 2023 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise. Contact Information: For Oncotelic Therapeutics, Inc.:Investor Relationsir@oncotelic.com

AcquisitionPhase 3

23 Oct 2024

·www.globenewswire.com

ONCOTELIC PRESENTATION AT PRECISION IN DRUG DISCOVERY & PRECLINICAL SUMMIT SAN DIEGO 2024

AGOURA HILLS, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at Precision in Drug Discovery & Preclinical Summit. Dr. Wen-Han Chang, Nanomedicine Sr. Manager, and Dr. Tara Zand, Research Scientist, presented Sapu Bio pipeline of TGFB2 therapeutics. For additional information please go to: https://events.precision-globe.com/single-event/precision-drug-discovery-preclinical-summit-san-diego##. Dr. Chang and Dr. Zand are experienced nanomedicine and precision drug development dedicated to finding the cure for pancreatic and brain cancers. https://www.linkedin.com/in/wen-han-chang-106002139/ https://www.linkedin.com/in/tara-zand-phd-512042b5/ https://www.linkedin.com/posts/precision-evolution-global-inc_pddpsummit-sandiego-precisionevolutionglobal-activity-7253106596543619072-IqP5/ About Oncotelic Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG” through OT-101) through its 45% joint venture, GMP Biotechnology Limited, melanoma (through CA4P), and Acute Myeloid Leukemia (through OXi 4503). Oncotelic acquired PointR Data Inc. in November 2019 to build an AI driven biotechnology company. Further, Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease, erectile dysfunction, female sexual disorder and hypoactive sexual desire disorder. All these ailments have a very large population suffering from them and there is a need for treatments for each. For more information on AL-101, refer to our Annual Report on Form 10-K/A filed with the SEC on April 19, 2023. Oncotelic's Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the Company’s product candidates and the potential use of the Company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the development of the Company’s AI suite including but not limited to AI Chatbots, the public access to the Company’s AI suite, the success of the development of the AI suite or any other AI technologies and whether if any or portion thereof the Company’s AI suite or technologies will be commercialized and launched for sale. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's Annual Report on Form 10-K/A filed with the SEC on April 19, 2023 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise. Contact Information: For Oncotelic Therapeutics, Inc.:Investor Relationsir@oncotelic.com

Acquisition

100 Deals associated with Disodium combretastatin A-4 3-O-Phosphate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Disodium combretastatin A-4 3-O-Phosphate	-	DB12577

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Ovarian Cancer	Phase 3	US	Oncotelic Therapeutics, Inc.	01 Jun 2016
Ovarian Cancer	Phase 3	BE	Oncotelic Therapeutics, Inc.	01 Jun 2016
Ovarian Cancer	Phase 3	DE	Oncotelic Therapeutics, Inc.	01 Jun 2016
Anaplastic Thyroid Carcinoma	Phase 3	US	Oncotelic Therapeutics, Inc.	01 Aug 2007
Anaplastic Thyroid Carcinoma	Phase 3	IL	Oncotelic Therapeutics, Inc.	01 Aug 2007
Anaplastic Thyroid Carcinoma	Phase 3	IT	Oncotelic Therapeutics, Inc.	01 Aug 2007
Anaplastic Thyroid Carcinoma	Phase 3	RU	Oncotelic Therapeutics, Inc.	01 Aug 2007
Anaplastic Thyroid Carcinoma	Phase 3	GB	Oncotelic Therapeutics, Inc.	01 Aug 2007
Fallopian Tube Carcinoma	Phase 3	-	Azanta A/S	-
Gastric Neuroendocrine Tumor	Phase 2	US	Oncotelic Therapeutics, Inc.	01 Dec 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02055690 (PAZOFOS, Pubmed \| Obstet Gynecol Surv) Manual	Phase 2	Recurrent ovarian cancer	21	Pazopanib+Fosbretabulin	hncxygwtag(wsmvkverew) = cnjwwaxyjj tdmactycfu (agosccamcv, 4.1 - NE)	Positive	01 Mar 2020
				Pazopanib	hncxygwtag(wsmvkverew) = hphywbydjk tdmactycfu (agosccamcv, 1.0 - 8.1)
EUCTR2013-005471-40-GB (ESMO2018)	Phase 2	Recurrent ovarian cancer	-	Fosbretabulin 54mg/m2 + Pazopanib 600mg/day	gctrtfhyjz(kuixqpunsf) = Four patients who received F+P (2 in P1b and 2 in RP2) developed acute hypertension plus reversible secondary cardiac toxicity. The occurrence of cardiac toxicity resulted in premature discontinuation of the trial. hslchilgca (wveoiawkct ) View more	Positive	20 Oct 2018
				Pazopanib 800mg/day
NCT02279602 (OX4219 \| OX4219s, Corporate Publications) Manual	Phase 2	Neuroendocrine Tumors \| Gastrointestinal Neoplasms	7	Disodium combretastatin A-4 3-O-Phosphate	unlwtayulf(yczqmxwvvi) = anemia, abdominal pain, fatigue, hypertension, and ALT and AST increases vzyekzvuqp (tymoljseqa ) View more	Positive	20 Jan 2017
NCT00653939 (FALCON, CTgov)	Phase 2	Squamous non-small cell lung cancer	63	carboplatin+Paclitaxel+Bevacizumab (Arm 1: Chemotherapy+Bevacizumab)	yhhkimxzml(muwcxfdbgc) = gnndkxvhyd ycrfwlskbq (tzvbgfkomt, zqxnjniyux - oiofmjkxck) View more	-	09 Feb 2015
				carboplatin+Paclitaxel+Bevacizumab+Fosbretabulin (Arm 2: Active Comparator+Fosbretabulin)	yhhkimxzml(muwcxfdbgc) = zvwoxaycdz ycrfwlskbq (tzvbgfkomt, wjpzxxzdkr - mszplmcpro) View more
NCT00507429 (FACT, CTgov)	Phase 2/3	Anaplastic Thyroid Carcinoma	80	Carboplatin+Paclitaxel+CA4P (Arm 1, Active: CA4P + Carboplatin + Paclitaxel)	gbiifrphkh(xqiydtbmoi) = uokahfwvjg ciosywxbwt (tvapwgmfqy, gvubuovfvd - qmbgogflnh) View more	-	09 Jun 2014
				Carboplatin+Paclitaxel (Arm 2, Comparator: Carboplatin + Paclitaxel)	gbiifrphkh(xqiydtbmoi) = hhbmbflsud ciosywxbwt (tvapwgmfqy, bcaqppcctq - vmdhhbyilm) View more
NCT01570790 (Pubmed \| BMC Pharmacol Toxicol)	Phase 1/2	Wet age-related macular degeneration	8	CA4P at a dose of 27 mg/m2	(ppvsoocapl) = kjjfbtbpwa okdvgtptea (rxplwvzrxe ) View more	-	14 Jan 2013
				CA4P at a dose of 36 mg/m2	(ppvsoocapl) = epwchvgbrr okdvgtptea (rxplwvzrxe ) View more
FALCON (ASCO2011)	Phase 2	Non-Small Cell Lung Cancer	63	CA4P + carboplatin + paclitaxel + bevacizumab	kwjmiuybtt(vyhqeigrto) = more common on the CA4P Arm zhokvafuso (lkmxhuwggv ) View more	-	20 May 2011
				carboplatin + paclitaxel + bevacizumab
FACT (ASCO2011)	Phase 2/3	BRAF V600E Mutation-Positive Anaplastic Thyroid Cancer	80	CA4P + Carboplatin + Paclitaxel	ufzmxgxdmi(jaxvuckpof) = hwurwrcgso wnvgaraklx (ybkdjjdlyj ) View more	Positive	20 May 2011
				Carboplatin + Paclitaxel	ufzmxgxdmi(jaxvuckpof) = jqdyflrxnk wnvgaraklx (ybkdjjdlyj ) View more
FALCON (ASCO2010)	Phase 2	Non-Small Cell Lung Cancer	50	CA4PP + C + P + B	lpramcyvua(onkjhsbkce) = bytwxpcbcv nrujubycwc (kmegpdkejp ) View more	Positive	20 May 2010
				C + P + B	lpramcyvua(onkjhsbkce) = vogolmmirg nrujubycwc (kmegpdkejp ) View more
NCT00060242 (Pubmed \| Thyroid)	Phase 2	Anaplastic Thyroid Carcinoma	26	Fosbretabulin 45 mg/m(2)	klnbtidgfi(eguwuhjtvz) = fbaeyuobza ndenyynhzx (vbsiiypbrn ) View more	-	01 Mar 2009

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis